823 related articles for article (PubMed ID: 25398058)
1. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
[TBL] [Abstract][Full Text] [Related]
2. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
[TBL] [Abstract][Full Text] [Related]
3. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia.
Ben-Chetrit E; Eldaim MA; Bar-Meir M; Dodin M; Katz DE
Int J Antimicrob Agents; 2019 Apr; 53(4):423-428. PubMed ID: 30572008
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
[TBL] [Abstract][Full Text] [Related]
5. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.
Kim SH; Kwon JC; Choi SM; Lee DG; Park SH; Choi JH; Yoo JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Ann Hematol; 2013 Apr; 92(4):533-41. PubMed ID: 23161391
[TBL] [Abstract][Full Text] [Related]
6. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
[TBL] [Abstract][Full Text] [Related]
7. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital.
Kader AA; Kumar A
Ann Saudi Med; 2005; 25(3):239-42. PubMed ID: 16119526
[TBL] [Abstract][Full Text] [Related]
9. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
[TBL] [Abstract][Full Text] [Related]
12. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
[TBL] [Abstract][Full Text] [Related]
13. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
[TBL] [Abstract][Full Text] [Related]
15. Pediatric extended spectrum β-lactamase infection: Community-acquired infection and treatment options.
Sethaphanich N; Santanirand P; Rattanasiri S; Techasaensiri C; Chaisavaneeyakorn S; Apiwattanakul N
Pediatr Int; 2016 May; 58(5):338-46. PubMed ID: 26513341
[TBL] [Abstract][Full Text] [Related]
16. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; de Cueto M; Ríos MJ; Hernández JR; Pascual A
Clin Infect Dis; 2006 Dec; 43(11):1407-14. PubMed ID: 17083012
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and antimicrobial resistance patterns of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated from blood cultures in an Istanbul University Hospital.
Koksal F; Ak K; Kucukbasmaci O; Samasti M
Chemotherapy; 2009; 55(4):293-7. PubMed ID: 19521075
[TBL] [Abstract][Full Text] [Related]
18. Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum beta-lactamase-producing organisms.
Lan CK; Hsueh PR; Wong WW; Fung CP; Lau YT; Yeung JY; Young GT; Su CC
J Microbiol Immunol Infect; 2003 Sep; 36(3):182-6. PubMed ID: 14582562
[TBL] [Abstract][Full Text] [Related]
19. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Labombardi VJ; Rojtman A; Tran K
Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
[TBL] [Abstract][Full Text] [Related]
20. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
